Reuters logo
8 months ago
BRIEF-Imugene to acquire immuno-oncology technology from Baker IDI institute
December 12, 2016 / 9:51 PM / 8 months ago

BRIEF-Imugene to acquire immuno-oncology technology from Baker IDI institute

Dec 13 (Reuters) - Imugene Ltd

* Imugene broadens pipeline with acquisition of immuno-oncology technology from Melbourne's Baker IDI heart and diabetes institute

* Baker IDI will receive 1.5 per cent of net revenues generated from approved cancer therapies using technology

* Imugene will pay no upfront costs for exclusive, worldwide rights to baker IDI's arginine modulators

* Acquisition of immuno-oncology technology-imu.ax Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below